Search results
Eisai and Bristol Myers Squibb terminate ADC development deal
Pharmaceutical Technology· 7 days agoEisai has announced the termination of its worldwide strategic collaboration with Bristol Myers ...
CAR-T landscape set to expand in 2024
Clinical Trials Arena· 7 days agoKey major players in this field are Novartis, Gilead, and Bristol Myers Squibb. Bristol Myers Squibb is one of the ...
Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition
Pharmaceutical Technology· 10 hours agoThe IBD field is quite crowded, with AbbVie’s Humira (adalimumab) being the top earner. However,...
5 FDA decisions to watch in the third quarter
BioPharma Dive· 6 days agoMultibillion-dollar buyouts from Bristol Myers Squibb and Gilead could yield new drugs for brain and liver diseases, while a new cell therapy may reach...
LOTTE BIOLOGICS breaks ground on biopharma plant in Incheon
Pharmaceutical Technology· 5 days agoFounded in 2022, LOTTE BIOLOGICS entered the contract development and manufacturing organisation...
Pipeline Moves: Alnylam’s Amvuttra approval prospects up after Phase III win
Clinical Trials Arena· 18 hours agoThe updated study protocol swapped Bristol Myers Squibb’s Opdivo (nivolumab) with toripalimab in a...
Hyderabad GCCs Lease 31% of Office Space in H1 2024 | Hyderabad News - Times of India
The Times of India· 4 days agoHyderabad: Global capability centres (GCCs), which have emerged as key drivers of office space absorption in the country, accounted for 60% or 3 million sq ft of the total 5 msft office space ...
Eli Lilly continues radiopharma push with $140m Radionetics partnership
Pharmaceutical Technology· 6 days agoBristol Myers Squibb (BMS) also made a big sign of its intent in this arena when it dropped $4.2bn...
Pentixapham acquires antibody discovery business from Glycotope
Pharmaceutical Technology· 5 days agoLilly has signed two high-profile deals for radiopharmaceuticals; a $140m partnership with...
